Drug Trial Radar · NCT07862621
A Clinical Trial of MK-6916 With Midazolam and Rosuvastatin in Healthy Participants (MK-6916-012)
Last checked: Nov 19, 2026Latest source record: Oct 7, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Not yet recruiting
Enrollment
18
Planned (sponsor's estimate)
Start
Nov 30, 2026
Primary completion
Feb 9, 2027
Study completion Feb 19, 2027
Sponsor
- Lead sponsor
- Merck Sharp & Dohme LLCMerck & Co. (MRK)
- Sponsor type
- Industry
- First posted
- Oct 7, 2026
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Basic science
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 55 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
Researchers are looking for new treatments for pain. The goal of this trial is to learn if MK-6916 changes what happens to the midazolam and rosuvastatin in healthy participants' bodies. Researchers will compare the amount of midazolam and rosuvastatin in a participant's body over time when they are given with and without MK-6916.
Conditions
- Healthy
Interventions
MidazolamDrug
Administered orally on Day 1 of Period 1 and on Days 2 and 14 of Period 2.
RosuvastatinDrug
Administered orally on Day 1 of Period 1 and Day 14 of Period 2.
MK-6916Drug
Administered orally once every 12 hours on Days 1 through 18 in Period 2.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Period 1: Area Under the Concentration-Time Curve From Time 0 to Infinity (AUC0-inf) of MidazolamTime frame: Predose and at designated timepoints up to approximately 24 hours
- Period 2: AUC0-inf of MidazolamTime frame: Predose and at designated timepoints up to approximately Day 15
- Period 1: AUC0-inf of RosuvastatinTime frame: Predose and at designated timepoints up to approximately 96 hours
- Period 2: AUC0-inf of RosuvastatinTime frame: Predose and at designated timepoints up to approximately Day 19
Locations
No sites are listed on the registry yet.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.